Published in AIDS Read on April 24, 2003
Editorial comment: when to discontinue maintenance therapy for OIs in patients on HAART. AIDS Read (2003) 0.75
Treatment of cryptococcal meningitis associated with the acquired immunodeficiency syndrome. National Institute of Allergy and Infectious Diseases Mycoses Study Group and AIDS Clinical Trials Group. N Engl J Med (1997) 5.88
Comparison of amphotericin B with fluconazole in the treatment of acute AIDS-associated cryptococcal meningitis. The NIAID Mycoses Study Group and the AIDS Clinical Trials Group. N Engl J Med (1992) 5.84
The safety and efficacy of zidovudine (AZT) in the treatment of subjects with mildly symptomatic human immunodeficiency virus type 1 (HIV) infection. A double-blind, placebo-controlled trial. The AIDS Clinical Trials Group. Ann Intern Med (1990) 5.55
Practice guidelines for the management of cryptococcal disease. Infectious Diseases Society of America. Clin Infect Dis (2000) 5.53
Accelerated bone mineral loss in HIV-infected patients receiving potent antiretroviral therapy. AIDS (2000) 3.39
Amphotericin B: current understanding of mechanisms of action. Antimicrob Agents Chemother (1990) 3.26
A preliminary study of ritonavir, an inhibitor of HIV-1 protease, to treat HIV-1 infection. N Engl J Med (1995) 2.88
An objective case definition of lipodystrophy in HIV-infected adults: a case-control study. Lancet (2003) 2.43
Pulmonary cryptococcosis in patients without HIV infection. Chest (1999) 2.31
Sex differences in nevirapine rash. Clin Infect Dis (2000) 2.09
A randomized trial of three antipneumocystis agents in patients with advanced human immunodeficiency virus infection. NIAID AIDS Clinical Trials Group. N Engl J Med (1995) 1.89
Amphotericin B: delivery systems. Antimicrob Agents Chemother (1990) 1.78
Use of paromomycin for treatment of cryptosporidiosis in patients with AIDS. Clin Infect Dis (1993) 1.77
Insulin resistance in HIV protease inhibitor-associated diabetes. J Acquir Immune Defic Syndr (1999) 1.61
Refractory mucosal candidiasis in patients with human immunodeficiency virus infection. Clin Infect Dis (1998) 1.60
Combination and monotherapy with zidovudine and zalcitabine in patients with advanced HIV disease. The NIAID AIDS Clinical Trials Group. Ann Intern Med (1995) 1.59
European AIDS Clinical Society (EACS) guidelines on the prevention and management of metabolic diseases in HIV. HIV Med (2008) 1.54
Bacteremia in hospitalized patients infected with the human immunodeficiency virus: a case-control study of risk factors and outcome. J Acquir Immune Defic Syndr Hum Retrovirol (1995) 1.47
Resistance to amphotericin B associated with defective sterol delta 8-->7 isomerase in a Cryptococcus neoformans strain from an AIDS patient. FEMS Microbiol Lett (1994) 1.38
Mucosal candidiasis caused by non-albicans species of Candida in HIV-positive patients. AIDS (1992) 1.29
Increased plasma gln and Leu Ra and inappropriately low muscle protein synthesis rate in AIDS wasting. Am J Physiol (1998) 1.27
The safety and efficacy of combination N-butyl-deoxynojirimycin (SC-48334) and zidovudine in patients with HIV-1 infection and 200-500 CD4 cells/mm3. J Acquir Immune Defic Syndr (1994) 1.22
Alterations in liver, muscle, and adipose tissue insulin sensitivity in men with HIV infection and dyslipidemia. Am J Physiol Endocrinol Metab (2005) 1.21
Persistent low-level viraemia and virological failure in HIV-1-infected patients treated with highly active antiretroviral therapy. HIV Med (2006) 1.21
Virologic responses to a ritonavir--saquinavir-containing regimen in patients who had previously failed nelfinavir. AIDS (1999) 1.15
Patterns of opportunistic infections in patients with HIV infection. J Acquir Immune Defic Syndr Hum Retrovirol (1996) 1.13
Refractory mucosal candidiasis in advanced human immunodeficiency virus infection. Clin Infect Dis (2000) 1.12
Alternating and intermittent regimens of zidovudine and dideoxycytidine in patients with AIDS or AIDS-related complex. Ann Intern Med (1993) 1.11
Detection of Epstein-Barr virus DNA in cerebrospinal fluid for diagnosis of AIDS-related central nervous system lymphoma. J Clin Microbiol (1995) 1.10
Guidelines for the treatment of cytomegalovirus diseases in patients with AIDS in the era of potent antiretroviral therapy: recommendations of an international panel. International AIDS Society-USA. Arch Intern Med (1998) 1.09
Blastomycosis in patients with the acquired immunodeficiency syndrome. Ann Intern Med (1992) 1.09
Level of cytomegalovirus (CMV) DNA in cerebrospinal fluid of subjects with AIDS and CMV infection of the central nervous system. J Infect Dis (1995) 1.07
Alterations in lipid kinetics in men with HIV-dyslipidemia. Am J Physiol Endocrinol Metab (2003) 1.06
Exposure of mice to live Pseudomonas aeruginosa generates protective cell-mediated immunity in the absence of an antibody response. J Immunol (1988) 1.05
Progressive multifocal leukoencephalopathy in patients with AIDS receiving highly active antiretroviral therapy. Clin Infect Dis (1999) 1.02
Pneumococcal endocarditis: report of a series and review of the literature. Rev Infect Dis (1986) 1.02
Prospects for preventing cryptococcosis in persons infected with human immunodeficiency virus. Clin Infect Dis (1995) 1.00
Impact of protease inhibitor therapy on HIV-related oropharyngeal candidiasis. AIDS (2000) 1.00
Serious Pseudomonas aeruginosa infections in patients infected with human immunodeficiency virus: a case-control study. Clin Infect Dis (1994) 0.97
T lymphocyte-mediated protection against Pseudomonas aeruginosa infection in granulocytopenic mice. J Clin Invest (1986) 0.96
Fellowship training in infectious diseases: a report from the regional and national meetings of infectious diseases division chiefs and program directors. Clin Infect Dis (1998) 0.96
Resistance exercise training reduces hypertriglyceridemia in HIV-infected men treated with antiviral therapy. J Appl Physiol (1985) (2001) 0.95
Two cases of blastomycosis from a common source: use of DNA restriction analysis to identify strains. J Infect Dis (1991) 0.94
Failure of prophylactic ganciclovir to prevent cytomegalovirus disease in recipients of lung transplants. J Infect Dis (1992) 0.91
Sub-optimal CD4 recovery on long-term suppressive highly active antiretroviral therapy is associated with favourable outcome. HIV Med (2009) 0.90
Cryptococcal disease: implications of recent clinical trials on treatment and management. AIDS Clin Rev (1997) 0.89
Suppressor T cells regulating the cell-mediated immune response to Pseudomonas aeruginosa can be generated by immunization with anti-bacterial T cells. J Immunol (1988) 0.87
The changing face of mycoses in patients with HIV/AIDS. AIDS Read (2001) 0.87
Changes in plasma amino acid concentrations in response to HIV-1 infection. Clin Chem (1994) 0.87
Post-exercise heart rate recovery in HIV-positive individuals on highly active antiretroviral therapy. Early indicator of cardiovascular disease? HIV Med (2007) 0.87
USPHS/IDSA guidelines for the prevention of opportunistic infections in persons infected with human immunodeficiency virus: an overview. USPHS/IDSA Prevention of Opportunistic Infections Working Group. Clin Infect Dis (1995) 0.86
Predictors of immunity after hepatitis A vaccination in HIV-infected persons. J Viral Hepat (2007) 0.85
In vitro T cell-mediated killing of Pseudomonas aeruginosa. V. Generation of bactericidal T cells in nonresponder mice. J Immunol (1987) 0.84
Editorial response: management of cryptococcal meningitis--have we answered all the questions? Clin Infect Dis (1996) 0.84
Hypothalamic-pituitary-adrenal function in patients receiving intermittent high dose prednisone therapy for lymphoma. Ir Med J (1984) 0.83
In vitro T cell-mediated killing of Pseudomonas aeruginosa. IV. Nonresponsiveness in polysaccharide-immunized BALB/c mice is attributable to vinblastine-sensitive suppressor T cells. J Immunol (1986) 0.83
Nelfinavir mesylate. Expert Opin Pharmacother (2000) 0.82
Risks of HIV infection in the health care setting. Annu Rev Med (1995) 0.82
Renal glomerulopathies associated with Hodgkin's disease. Cancer (1985) 0.82
Cryptococcosis. Adv Pharmacol (1997) 0.81
Serum leptin concentrations in human immunodeficiency virus-infected men with low adiposity. Metabolism (1997) 0.81
Alterations in spliced and unspliced HIV-1-specific RNA detection in peripheral blood mononuclear cells of individuals with varying CD4-positive lymphocyte counts. AIDS Res Hum Retroviruses (1993) 0.81
Oesophageal ulceration in Behçet's disease presenting with haemorrhage. Ir J Med Sci (1987) 0.80
In vitro T cell-mediated killing of Pseudomonas aeruginosa. III. The role of suppressor T cells in nonresponder mice. J Immunol (1986) 0.80
Ototoxicity associated with dideoxycytidine. Lancet (1990) 0.79
The use of alternative therapies by HIV-positive patients attending the St. Louis AIDS Clinical Trials Unit. Mo Med (1991) 0.79
Failure of high-dose oral acyclovir with or without immune globulin to prevent primary cytomegalovirus disease in recipients of solid organ transplants. Am J Med (1993) 0.79
Risk factors for dideoxynucleoside-induced toxic neuropathy in patients with the human immunodeficiency virus infection. J Acquir Immune Defic Syndr Hum Retrovirol (1995) 0.78
Molecular epidemiology of mucosal candidiasis in HIV-positive women. AIDS Res Hum Retroviruses (1997) 0.78
Ganciclovir for cytomegalovirus after heart transplantation. N Engl J Med (1992) 0.77
A prospective study of discontinuing primary and secondary Pneumocystis carinii pneumonia prophylaxis after CD4 cell count increase to > 200 x 106 /l. AIDS (2001) 0.77
Prophylaxis for HIV-related infections: a work in progress. Ann Intern Med (1996) 0.77
Timing of antiretroviral therapy. Use of Markov modeling and decision analysis to evaluate the long-term implications of therapy. AIDS (2001) 0.76
Elevated lactate levels in hospitalized persons with HIV infection. AIDS Res Hum Retroviruses (2001) 0.76
The interaction of opportunistic infections and HIV replication. AIDS (1999) 0.76
Guidelines for the design and conduct of AIDS clinical trials. AIDS Clinical Trials Group. Clin Infect Dis (1993) 0.75
Clinical research in the acquired immunodeficiency syndrome. Ann Intern Med (1995) 0.75
Symptomatic cytomegalovirus infection in renal transplant recipients given either Minnesota antilymphoblast globulin (MALG) or OKT3 for rejection prophylaxis. Am J Kidney Dis (1993) 0.75
Major blinding complication of acquired immune deficiency syndrome (AIDS) Retina (1997) 0.75
Human immunodeficiency virus infection. Clinical diagnosis. Mo Med (1989) 0.75
Treatment of acute cryptococcal disease. Expert Opin Pharmacother (2001) 0.75
Progenitor cell types in HIV-1 infection: bioactivity and emerging targets for treatment. Curr HIV Res (2009) 0.75
Addressing current challenges in haemophilia care: consensus recommendations of a European Interdisciplinary Working Group. Haemophilia (2005) 0.75
Antifungal treatment for cryptococcal meningitis. Intern Med J (2006) 0.75
Aspergillosis. J Int Assoc Physicians AIDS Care (1997) 0.75
Zidovudine. Mo Med (1989) 0.75
A phase II study of recombinant human interferon-alpha 2a and zidovudine in patients with AIDS-related Kaposi's sarcoma. AIDS Clinical Trials Group. J Acquir Immune Defic Syndr Hum Retrovirol (1996) 0.75
Prophylaxis of opportunistic infections. Infect Dis Clin North Am (2000) 0.75
Initial clinical management of the HIV-infected patient. Mo Med (1989) 0.75
A pilot study of the management of uncomplicated candidemia with a standardized protocol of amphotericin B. Clin Infect Dis (1999) 0.75
HIV expertise: a roundtable. AIDS Clin Care (2001) 0.75
Rifabutin induced vitritis in AIDS patients. Ocul Immunol Inflamm (1996) 0.75